What We're Reading
The following articles caught my eye in the first part of February, most notably, we are close to having a pill form of brexanolone (Zulresso), called zuranolone. Zulresso was the first drug on the market developed specifically for maternal depression, which exists only in an intravenous form. We’re also highlighting an article from Health Affairs that describes an increase in PCP visits for mental health concerns, something we surely are seeing in obstetrics too. Finally, the tragedy in Massachusetts involving a suspected case of postpartum psychosis (likely triggered not only by lack of sleep, but the 10+ drugs this mother was prescribed) has inspired a lawmaker to introduce a bill to put such mothers in intensive treatment programs rather than in jail.
Read More